---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001764"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:56.497858+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion reports preliminary 2025 revenue up 20-23%, U.S. sales up 35-38%; provides 2026 OpEx guidance

## Summary
- Preliminary 2025 U.S. net product sales $156-160M, up 35-38% YoY; total revenue $400-408M, up 20-23%.
- Cash and equivalents ~$168M at year-end 2025; completed $75M capital raise in 2025.
- 2026 operating expenses expected $210-245M, including $15M non-cash stock compensation.
- Patent settlements with four ANDA filers restrict generic entry until April 2040; no remaining patent challenges.
- R&D pipeline: nominated ESP-2001 (ACLY inhibitor) for primary sclerosing cholangitis; blockbuster potential >$1B.

## SEC filing metadata
- accession: 0001628280-26-001764
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828026001764/0001628280-26-001764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828026001764/espr-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001764
- JSON: https://secwatch.observer/filing/0001628280-26-001764.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.